HTLV-1 is a significant global health problem but remains largely confined to endemic areas and risk groups. However, increasing migration may mean that the virus will be encountered more frequently in areas traditionally thought of as virtually free of HTLV-1. In this review we discuss the epidemiology, transmission, clinical features, diagnosis and treatment of HTLV-1, focussing specifically on the neurological manifestations. We highlight the circumstances in which HTLV-1 should be suspected and outline the current understanding of HTLV-1-associated myelopathy and other neurological presentations.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Read the full text or download the PDF:
Other content recommended for you
- Hospital admissions for human T-cell lymphotropic virus type-1 (HTLV-1) associated diseases in Dominica
- HTLV-1-associated myelopathy in a solid organ transplant recipient
- Sarcoidosis and HTLV-1 infection
- Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls
- HTLV-1 infections
- Complete remission of a relapsing adult T cell leukaemia following treatment of a secondary acute promyelocytic leukaemia: towards a reappraisal of arsenic trioxide and all-transretinoic acid?
- The association of HTLV-1 infection, persistent intestinal infection with Strongyloides stercoralis and gastrointestinal lymphoma
- HTLV-1 encephalitis
- Neurological morbidity among human T-lymphotropic-virus-type-1-infected individuals in a rural West African population
- HTLV-1 encephalomyelitis; a case report of a treatable manifestation of HTLV-1 infection